Loading...
XSHE300318
Market cap593mUSD
Jan 10, Last price  
5.33CNY
1D
-3.79%
1Q
-4.14%
Jan 2017
-41.17%
IPO
87.92%
Name

Beijing Bohui Innovation Biotechnology Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300318 chart
P/E
—
P/S
4.16
EPS
—
Div Yield, %
1.17%
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
10.94%
Revenues
1.05b
+31.35%
24,509,85225,875,88029,366,27139,398,13751,462,66363,583,36878,406,66098,121,947113,760,681106,870,485100,969,495268,846,009404,048,600443,754,419622,093,848628,340,031738,717,388714,748,462795,932,4951,045,429,099
Net income
-25m
13,789,75813,917,59012,954,76122,297,46539,854,41225,911,98633,743,60644,776,08150,954,46654,256,73338,138,79411,882,00823,599,15238,850,99069,438,2862,542,7557,503,97600-24,929,391
CFO
137m
+236.50%
9,401,34623,297,46916,040,74922,785,85132,232,68346,893,66361,282,91255,081,30931,048,91188,950,52277,969,56500086,137,577887,77740,718,935137,017,197
Dividend
Jul 12, 20180.005012 CNY/sh
Earnings
May 16, 2025

Profile

Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. It offers GenPlex, a microfluidic automated nucleic acid detection system, immunofluorescence detection products, and human trace element detection products; and chemical analysis products, such as atomic fluorescence spectrometer and photometer, mass spectrometers, chip ion sources, microfluidic flow chemical analysis systems, life sciences related consumables, and ICP spectroscopy. The company was formerly known as Beijing Bohui Innovation Biotechnology Co., Ltd. and changed its name to Beijing Bohui Innovation Biotechnology Group Co., Ltd. in August 2021. Beijing Bohui Innovation Biotechnology Group Co., Ltd. was founded in 2001 and is headquartered in Beijing, China.
URL
https://www.bohui-tech.com/
IPO date
May 23, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,045,429
31.35%
795,932
11.36%
Cost of revenue
774,650
762,808
Unusual Expense (Income)
NOPBT
270,780
33,125
NOPBT Margin
25.90%
4.16%
Operating Taxes
18,047
4,142
Tax Rate
6.66%
12.50%
NOPAT
252,733
28,983
Net income
(24,929)
 
Dividends
(51,148)
Dividend yield
1.00%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
365,505
456,719
Long-term debt
419,907
351,535
Deferred revenue
30,897
16,733
Other long-term liabilities
2,017
3,391
Net debt
668,669
464,028
Cash flow
Cash from operating activities
137,017
40,719
CAPEX
(197,545)
Cash from investing activities
(169,275)
Cash from financing activities
8,249
172,603
FCF
182,376
(1,488,770)
Balance
Cash
104,926
113,600
Long term investments
11,817
230,626
Excess cash
64,471
304,429
Stockholders' equity
1,787,907
1,748,397
Invested Capital
3,054,911
2,785,086
ROIC
8.66%
1.41%
ROCE
8.39%
1.04%
EV
Common stock shares outstanding
817,357
816,900
Price
6.25
6.84%
5.85
-40.97%
Market cap
5,108,482
6.90%
4,778,868
-40.97%
EV
6,748,158
6,173,242
EBITDA
394,178
142,490
EV/EBITDA
17.12
43.32
Interest
27,622
42,254
Interest/NOPBT
10.20%
127.56%